The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.

Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication ...

The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...

The approval is for Eylea to treat macular edema following retinal vein occlusion with up to every eight-week dosing after an initial dosing period. The FDA also approved a monthly dosing option for ...

Treatment with high dose aflibercept 8 mg can lead to similar visual outcomes with fewer injections for patients with RVO.

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...